Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-Week, open-label, observational study

Current Medical Research and Opinion

Volumn 25, Issue 5, 2009, Pages 1131-1142

  Bingham III, Clifton O ^a   Ince, Akgun ^b   Haraoui, Boulos ^c   Keystone, Edward C ^d   Chon, Yun ^e   Baumgartner, Scott ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e AMGEN INC   (United States)

Author keywords

Etanercept; Infliximab; Rheumatoid arthritis; Switch; TNF antagonist

Indexed keywords

CEFTRIAXONE; CORTICOSTEROID; DRUG ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; LYMPHOTOXIN; METHOTREXATE; MOXIFLOXACIN; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; APPENDICITIS; ARTICLE; BENIGN TUMOR; BREAST DISEASE; BRONCHITIS; CLINICAL TRIAL; CYST; DEATH; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART DISEASE; HUMAN; INFECTION; INFESTATION; INFLAMMATION; INFLUENZA; INJURY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; NEOPLASM; NUTRITIONAL DISORDER; OBSERVATIONAL STUDY; OPEN STUDY; POLYP; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINUSITIS; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PATIENT COMPLIANCE; RECEPTORS, TUMOR NECROSIS FACTOR; SALVAGE THERAPY; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 67649406107     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902841010     Document Type: Article

References (44)

1. Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust 2005;183:205-208 (Pubitemid 41150331)
2. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005;19:47-57 (Pubitemid 40432507)
3. Trent JT, Kerdel FA. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs 2005; 17:97-107
4. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003;21:241-248 (Pubitemid 36519574)
5. Wallis RS, Broder M, Wong J, et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005;41 (Suppl. 3):S194-8 (Pubitemid 41022090)
6. Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005;34:7-11 (Pubitemid 40502154)
7. van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-1198 (Pubitemid 37500626)
8. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29
9. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45:1558-1565 (Pubitemid 44817065)
10. Kamal KM, Madhavan SS, Hornsby JA, et al. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine 2006;doi:10.1016/j.jbspin.2006.05.002
11. Villenueve E, Haraoui B. Switching between TNF-a inhibitors in the treatment of rheumatoid arthritis. Int J Adv Rheumatol 2006;4:2-8
12. Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23:795-800 (Pubitemid 43040507)
13. Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-2359 (Pubitemid 39603081)
14. Buch MH, Bingham SJ, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007;57:448-453 (Pubitemid 46682532)
15. Di Poi E, Perin A, Morassi MP, et al. Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 2007;25:85-87 (Pubitemid 46477490)
16. Cantini F, Niccoli L, Benucci M, et al. Switching from infliximab to once-weekly administration of 50mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006;55: 812-816 (Pubitemid 44619197)
17. Delaunay C, Farrenq V, Marini-Portugal A, et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005;32: 2183-2185 (Pubitemid 41587865)
18. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40
19. Disease Activity Score in Rheumatoid Arthritis [Last accessed 10 November 2008]. Available at: http://www.das-score.nl/ www.das-score.nl/index.html
20. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
21. Patton A, Mullenix MC, Swanson SJ, et al. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005;304:189-195 (Pubitemid 41262233)
22. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593 (Pubitemid 32162981)
23. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-486
24. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-681 (Pubitemid 38296553)
25. Pincus T. Advantages and limitations of quantitative measures to assess rheumatoid arthritis: joint counts, radiographs, laboratory tests, and patient. Bull NYU Hosp Jt Dis 2006;64:32-39 (Pubitemid 44625530)
26. Wolfe F, Michaud K, Pincus T, et al. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005;52:3873-3879 (Pubitemid 41798226)
27. Torikai E, Kageyama Y, Takahashi M, et al. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:761-764 (Pubitemid 43985348)
28. Durez P, Nzeusseu Toukap A, Lauwerys BR, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis 2004;63:1069-1074 (Pubitemid 39120356)
29. Macias I, Garcia-Perez S, Ruiz-Tudela M, et al. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol 2005;32:2102-2108 (Pubitemid 41587852)
30. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141-147 (Pubitemid 27306284)
31. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259 (Pubitemid 29063266)
32. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46:1443-1450 (Pubitemid 34620189)
33. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50:353-363 (Pubitemid 38198818)
34. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123 (Pubitemid 41317434)
35. Buch MH, Seto Y, Bingham SJ, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005;52:42-48 (Pubitemid 40129231)
36. Pincus T, Sokka T. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin Exp Rheumatol 2005;23(5 Suppl. 39):S1-9 (Pubitemid 46661463)
37. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935-942 (Pubitemid 40676507)
38. Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine 2007;74:249-253 (Pubitemid 46720043)
39. Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-1356 (Pubitemid 34754607)
40. Burmester GR, Monteagudo Saez I, Malaise M, et al. Adalimumab (Humira®) is effective in patients who have previously been treated with TNF-antagonists (etanercept and/or infliximab) in widespread clinical practice: 12-week outcomes in the REACT trial. Ann Rheum Dis 2005;64 (Suppl. III):423
41. Baumgartner SW, Fleischmann RM, Moreland LW, et al. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 2004;31:1532-1537 (Pubitemid 39006633)
42. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-2792 (Pubitemid 44497757)
43. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-560 (Pubitemid 23102493)
44. van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007; 66:253-256 (Pubitemid 46226064)